/
Sen. Ron Wyden Issues Consumer Protection Inquiries to Crypto Exchanges
Published on
Sen. Ron Wyden Issues Consumer Protection Inquiries to Crypto Exchanges

Sen. Ron Wyden, chairman of the Senate Committee on Finance, has called on major cryptocurrency companies to provide information on their customer protection measures following the bankruptcy of the FTX exchange.

Wyden sent letters to the leaders of Binance, Bitfinex, Coinbase, Gemini, Kraken and KuCoin and asked for information on how they plan to protect customers using their products in the event of financial failures, the senator’s office said Tuesday.

The cryptocurrency exchanges have until Dec. 12 to disclose the policies and practices they have in place to guard against market manipulation and suspicious trading, explain whether they separate assets bought or sold on their platform from their subsidiaries or affiliates and provide information on how they use consumer data.

Wyden also requested details on the companies’ real estate acquisitions financed by customer funds,

“As Congress considers much-needed regulations for the crypto industry, I will focus on the clear need for consumer protections along the lines of the assurances that have long existed for customers of banks, credit unions and securities brokers,” Wyden promised.

/
NASA’s Artemis I Space Launch System Rocket Reaches Mission Goals
Published on
NASA’s Artemis I Space Launch System Rocket Reaches Mission Goals

NASA reported on Wednesday that the initial launch of its Space Launch System rocket met expectations in transporting the uncrewed Orion spacecraft around the moon.

SLS is integral to the Artemis I mission, which sets the stage for the agency’s plan to revive manned lunar landing expeditions.

Artemis mission manager Mike Sarafin said that the rocket’s systems “performed as designed and as expected in every case.” Its twin solid booster motors enabled SLS to travel more than 27 miles upon take-off. It achieved its speed targets, reaching approximately 4,000 mph in over two minutes before booster separation.

Built by Lockheed Martin, the Orion capsule exceeded its required travel distance after SLS transported it to within three miles of its targeted orbit altitude. The moon rocket’s core stage, developed by Boeing, met all of its goals, as did the four RS-25 engines supplied by Aerojet Rocketdyne.

Artemis I launched on Nov. 16 at the Kennedy Space Center in Florida, and is set to conclude on Dec. 11. Engineers will continue to analyze the travels of SLS in the next several months and apply relevant findings to future Artemis expeditions.

/
Air Force Team Develops ‘Spirit Realm’ Software Factory for B-2 Bomber
Published on
Air Force Team Develops ‘Spirit Realm’ Software Factory for B-2 Bomber

An innovation team at the Air Force Life Cycle Management Center tasked with producing technology for the B-2 Spirit Stealth bomber has established a new software factory to bring enhancements to the long-range aircraft fleet.

The Spirit Realm B-2 Software Factory, conceived by the B-2 Software Maintenance and Innovation Team in partnership with Northrop Grumman, aims to reduce flight test risks and timelines, cut back on flight test burdens, increase integrated functional capability quality and enable upgrades to the B-2 Spirit, the Air Force Global Strike Command said Wednesday.

The software factory utilizes the Department of Defense’s DevSecOps reference design to guide the creation and testing of the B-2 software.

“After the development and implementation of the Spirit Realm, B-2 software is now developed, tested and integrated using modern DevSecOps and Scaled Agile principles and a single software baseline,” shared Capt. Joel Graley, the lead for the B-2 Software Maintenance and Innovation Team. 

“This approach enables the fielding of the highest priority capabilities at an unprecedented pace, and ensures the B-2 can rapidly field new capabilities to counter emerging threats,” Graley continued.

Due to the introduction of the new facility, the Air Force reported software upgrade timelines were cut from 24 months to three months and the number of software defects found during regression testing were totally eradicated.

//
SAIC Recognized as DOD JADC2 Contributor in Frost & Sullivan Report; Michael LaRouche Quoted
Published on
SAIC Recognized as DOD JADC2 Contributor in Frost & Sullivan Report; Michael LaRouche Quoted

SAIC has been selected as a ‘company to watch’ in the area of supporting the Department of Defense Joint All-Domain Command and Control strategy by Frost & Sullivan.

This decision makes SAIC one of only three companies who received this recognition, the Reston, Virginia-based organization announced on Thursday.

“For JADC2 to succeed, the Department of Defense needs experts in advanced capabilities in network virtualization, optimized delivery, software integration, cloud operations and cyber defense. That, and an unparalleled understanding of the challenge, is exactly what we bring to the table,” emphasized Michael LaRouche, president of SAIC’s national security and space sector and a two-time Wash100 Award winner.

Expertise in IT modernization, space, digital engineering and Cloud One has made it possible for the company to support JADC2’s core mission areas while collaborating with the federal government to modernize legacy command and control systems, which enables faster decision making and higher rates of mission success.

“SAIC received recognition as best in class around Artificial Intelligence and digital engineering innovations, its deep DoD mission understanding and its commercial technology integration capabilities, all of which are required for leading a multi-domain program like JADC2,” said Brad Curran, aerospace and defense principal analyst at Frost & Sullivan.

SAIC is currently providing services that satisfy four areas within the JADC2 strategy. These are cloud migrations and modernizations, tactical edge services, data transport through ultra-high-bandwidth, ultra-high-speed transmission and data collection and management, per the company’s website.

The enterprise has become a notable partner of the cross-departmental endeavor. In 2022 alone, SAIC received over $500 million in contract awards related to the command and was included in numerous multi-organization contracts including the Advanced Battle Management System Digital Infrastructure Consortium and as the prime contractor for the Falconer Air Operations Center Weapon System Sustainment project.

As part of the consortium, SAIC is working alongside four additional contractors to develop and implement secure processing, data management, connectivity and open architecture. Under the Falconer Air Operations Weapon System Sustainment award, the company is tasked with providing weapon systems maintenance services for air operations centers.

CBO Report: Economic Growth to Slow Down in 2023, Pick Up in 2024
Published on
CBO Report: Economic Growth to Slow Down in 2023, Pick Up in 2024

The Congressional Budget Office adjusted its economic growth outlook for 2023 on account of inflation, higher interest rates and an uptick in unemployment that occurred in the second half of 2022.

In a report released Wednesday, CBO stated that compared to its assessment in May, rates of interest, unemployment and inflation will be greater in the next two years.

Based on data available through Nov. 16, economic growth will be slower in 2023 than previously expected, but it will recover in 2024. The agency had a more positive outlook using information it obtained through March 2, 2022.

CBO’s current assessment projects real gross domestic product growth to be lower than 2.2 percent in 2023, but higher than 1.5 percent in 2024. The national unemployment rate in 2023 and 2024 could be greater than 3.6 percent and 3.8 percent, respectively. Interest rates on Treasury bills for a three-month period are expected to range from 3.4 percent to 5.6 percent next year, and 1.7 percent to 4.8 percent the following year.

The agency is refining the preliminary results in preparation for the publication of its annual Budget and Economic Outlook.

////
Robert Storch Confirmed as DOD Inspector General
Published on
Robert Storch Confirmed as DOD Inspector General

The Senate voted 92-3 Wednesday to confirm Robert Storch, inspector general at the National Security Agency, as IG of the Department of Defense.

President Joe Biden nominated Storch to the IG role at DOD in November 2021.

Storch assumed responsibilities as IG at NSA in January 2018 and has helped advance efforts to improve the transparency of the IG office’s work, such as establishing a public website and public release of unclassified versions of semiannual reports to Congress.

He was deputy IG at the Department of Justice and served as the first whistleblower ombudsperson at DOJ’s IG office.

He served for more than two decades as a federal prosecutor at the U.S. Attorney’s Office for the Middle District of Florida and the U.S. Attorney’s Office for the Northern District of New York. He also worked at law firms Covington and Burling and Bond, Schoeneck and King.

Defense News reported Storch’s confirmation marks the end of a nearly seven-year vacancy for a full-time IG at the Pentagon.

Sean O’Donnell, the Environmental Protection Agency’s current IG, has been serving as acting inspector general at DOD since April 2020.

//
DOD Releases Zero Trust Architecture Implementation Strategy; David McKeown Quoted
Published on
DOD Releases Zero Trust Architecture Implementation Strategy; David McKeown Quoted

The Department of Defense has issued its Zero Trust Strategy and Roadmap, which details its plan to move away from traditional network security approaches to zero trust architecture.

The list of goals—expected to be completed within the next five years—is intended to reduce network attack surfaces, allow risk management and necessary data-sharing in collaborative environments and contain and limit adversary activities, the department announced on Monday.

“With the publication of this strategy we have articulated the ‘how’ that can address clear outcomes of how to get to zero trust — and not only accelerated technology adoption, as discussed, but also a culture of zero trust at DOD and an integrated approach at the department and the component levels,” said David McKeown, acting principal deputy chief information officer and deputy CIO for cybersecurity at DOD.

David McKeown is confirmed to keynote the Cloud Security Forum hosted by ExecutiveBiz on March 22, 2023. Click here to register!

Explaining the idea behind zero trust, McKeown said that the architecture is based on the assumption that a breach has already occurred within cyber boundaries and responding to threats in an appropriate manner.

The implementation of zero trust architecture has become an increasing priority within federal organizations following a May 2021 Executive Order, which called upon federal organizations to establish this method as soon as possible.

According to McKeown, the department’s new strategy was developed over the course of a year and included the creation of the Zero Trust Portfolio Management Office, which was established earlier this year.

Randy Resnick, director of the office, will oversee much of the plan’s implementation.

“If we compare this to our home security, we could say that we traditionally lock our windows and doors and that only those with the key can gain access,” Resnick stated.

“With zero trust, we have identified the items of value within the house and we place guards and locks within each one of those items inside the house. This is the level of security that we need to counter sophisticated cyber adversaries,” he added.

The roadmap identifies four strategic goals that enumerate what the Department of Defense will do to achieve its zero trust objectives. These include zero trust cultural adoption to equip the agency’s people with a zero trust mindset; securing and defending its information systems by incorporating zero trust into new and old systems; technology acceleration; and zero trust enablement.

Resnick stated that the roadmap’s development was a multi-organizational endeavor, which included the National Security Agency, the Defense Information Systems Agency, the Defense Manpower Data Center, the U.S. Cyber Command and the military services.

The collaborative effort resulted in the development of 45 capabilities and over 100 activities enabled by those capabilities, many of which are intended to be utilized to achieve baseline compliance with zero trust architecture.

“Each capability, the 45 capabilities, resides either within what we’re calling ‘target,’ or ‘advanced’ levels of zero trust. DOD zero trust target level is deemed to be the required minimum set of zero trust capability outcomes and activities necessary to secure and protect the department’s data, applications, assets and services, to manage risks from all cyber threats to the Department of Defense,” Resnick explained.

Every agency within the department will be required to comply with the plan’s baseline targets for zero trust implementation. Select agencies may be expected to reach more advanced standards.

“We want to encourage those who have a greater need to secure their data to adopt this advanced level,” McKeown emphasized.

Resnick stressed that the baseline standards do not represent a lower standard of security and still indicates a full adaptation of zero trust architecture methods able to identify and stop the adversary. These standards are also flexible as the plan leaves room for requirements to be added or modified.

“The target level of zero trust is going to be that ability to contain the adversary, prevent their freedom of movement from not only going laterally but being able to even see the network, to enumerate the network and to even try to exploit the network,” he added.

The plan’s implementation will better equip the department to prevent adversaries’ attacks and minimize damage by 2027, according to Resnick.

What are the Top GlaxoSmithKline Government Contracts?
Published on
What are the Top GlaxoSmithKline Government Contracts?

GlaxoSmithKline, also known as GSK, is a pharmaceutical and biotechnology manufacturer. The company has developed vaccine supply doses for illnesses such as influenza, malaria, and COVID-19 and has several ongoing clinical trials. See the list of the top GlaxoSmithKline government contracts for the US government.

1. US Army Contracted for Storage, Procurement, and Distribution of Sotrovimab

  • Federal agency: US Army
  • Contract type: Firm-fixed-price contract
  • Value: $279.86 million
  • Contract date: September 29, 2021
  • Contract period: 1 year

GlaxoSmithKline was assigned to procure, store, and distribute Sotrovimab, a monoclonal antibody neutralizer treatment. The government purchase was completed in Durham, North Carolina on May 19, 2022. The contract was one of the many purchases of Sotrovimab made by the US government.

The contracting activity for the one-year award was the Army Contracting Command in Aberdeen Proving Ground, Maryland. The project was funded from Defense Production Act purchases, defense funds for fiscal 2021, which were obligated to the total amount of $279.86 million at the time of the award.

2. US ArmyAwarded The Procurement of Sotrovimab Additional Doses

  • Federal agency: US Army
  • Contract type: Modification to the contract
  • Value: $975.11 million
  • Contract date: January 10, 2022
  • Contract period: 8 months

The US Army awarded a $975.11-million contract to procure 340,048 additional doses of Sotrovimab. The project was completed on September 30, 2022, and was funded by the Department of Health and Human Services Office provided by the American Rescue Plan Act of 2021. The award also included an option for additional 715,680 doses by June 30, 2022.

The initial firm-fixed contract to purchase Sotrovimab for COVID-19 treatment was worth $651.09 million. The one-year contract was awarded on November 15, 2021, and was completed on March 31, 2022. Funding came from Defense Production Act funds for fiscal 2010 and was obligated at the time of the award.

The initial and follow-on contract awards were worked on in Durham, North Carolina. The Army Contracting Command in Aberdeen Proving Ground, Maryland was the contracting activity for both projects.

3. US Army Finalized the Procurement of COVID-19 Vaccines to Support Military Personnel

  • Federal agency: US Army
  • Contract type: Firm-fixed-price contract
  • Value: $342 million
  • Contract date: July 30, 2020
  • Contract period: 1 year

GlaxoSmithKline was contracted to procure COVID-19 vaccines from different vaccine vendors and manufacturers to support military personnel in several locations across the United States and the world. The mass quantity procurement was completed on February 28, 2021, in Research Triangle Park, North Carolina.

The Army Contracting Command in Newark, New Jersey served as the contracting activity for the project. Funding came from Army research, development, test, and evaluation funds for fiscal 2020, which was obligated to be $342 million at the time of the award.

4. DLA Ordered Injectable Influenza Vaccines for the US Military

  • Federal agency: Defense Logistics Agency/ Department of Defense
  • Contract type: Firm-fixed-price, indefinite-quantity contract
  • Value: $44.50 million
  • Contract date: February 23, 2021
  • Contract period: 1 year

GlaxoSmithKline and Seqirus Inc. were awarded a competitive acquisition contract under a solicitation for the government purchase of injectable influenza vaccines. GSK received $44.50 million, while Seqirus received $22 million from the defense working capital funds for fiscal 2021-2022. The ordering period’s end date was on February 22, 2022.

A year after, on February 25, 2022, both companies were awarded another contract to supply doses of injectable influenza vaccines. The funding was obligated from the defense working capital funds for fiscal 2022-2026, giving GSK $33.80 million and Seqirus $8.64 million. The ordering period’s end date is on February 24, 2023.

All contracts only had a one-year duration with no option periods. Works have been performed in Pennsylvania, New Jersey, and North Carolina. The Defense Logistics Agency Troop Support served as the contracting activity for all projects.

The Department of Defense inoculates injectable influenza vaccines for the Army, Air Force, Navy, Marine Corps, and Coast Guard to keep the force in top health condition during their mission and deployment in and out of the United States. The US government has initiated the military health systems for more than 230 years.

5. DLA Signed a Deal for Multi-dose Influenza Vaccine Vials and Prefilled Syringes

  • Federal agency: Defense Logistics Agency
  • Contract type: Firm-fixed-price, indefinite-quantity contract
  • Value: $17.12 million
  • Contract date: June 8, 2016
  • Contract period: 1 year

The Defense Logistics Agency Troop Support finalized a deal with GlaxoSmithKline for multi-dose influenza vaccine vials to be used by the Army, Navy, Air Force, Marine Corps, and other federal civilian agencies. The contract was completed on June 7, 2017.

Previously, GSK was awarded a contract for influenza vaccine and prefilled syringes on June 15, 2015. The firm-fixed-price indefinite-quantity contract was worth $11.78 million and was completed on June 14, 2016.

Both contracts were competitive acquisitions and were selected among four responses. The performance location was in North Carolina, with an appropriation type of defense working capital funds for fiscal 2015-2017.

Frequently Asked Questions:

What is GlaxoSmithKline?

GlaxoSmithKline | GSK

GlaxoSmithKline was formed in 2000 with the merger of Glaxo Wellcome and SmithKline Beecham. Previously, the pharmaceutical giants were separate companies of Glaxo, Wellcome, SmithKline, and Beecham. Almost 22 years after the merger, the company ranks 294th on the Fortune 500 list in 2022.

While its corporate headquarters is located in London, England, GSK has a significant presence in the United States with two corporate hubs, employing approximately 15,000 people. The company offers expanded nationwide access to its pharmaceutical products across commercial, research & development, manufacturing, and corporate functions.

What is GlaxoSmithKline’s Sotrovimab?

Sotrovimab is a neutralizing monoclonal antibody developed by GlaxoSmithKline and Vir Biotechnology. It serves as an early treatment against COVID-19 and prevents the virus from getting into the lungs to cause an infection.

Sotrovimab acts like a clone of human antibodies, sticking to the spike protein of the virus to neutralize it. Once the treatment takes effect, it can prevent reinfection from COVID-19 for at least four weeks. Sotrovimab is branded under Xevudy in the United Kingdom.

Does GSK’s Sotrovimab have FDA approval?

The Food and Drug Administration issued Emergency Use Authorization (FDA EUA) for Sotrovimab on May 26, 2021. While still unapproved, FDA allowed the treatment use of the medicine for mild-to-moderate COVID-19 in adults and pediatric patients at least 12 years old or 40 kgs. The FDA EUA applies only to positive cases where patients haven’t been hospitalized or require respiratory support.

Does GlaxoSmithKline have a COVID-19 vaccine?

Aside from offering Sotrovimab for COVID-19 treatment, GlaxoSmithKline provides the technology to improve the immune system’s response to the vaccine. GSK’s adjuvant technology increases the production of the vaccine, as it can develop large quantities of the vaccine with only a tiny amount. The company has offered this technology with Sanofi, Medicago, and SK bioscience.

At the same time, GlaxoSmithKline has worked with CureVac to develop mRNA vaccines against multiple COVID-19 variants. The preclinical test results were announced in 2021, while the clinical trial commenced in 2022. The partnership aims to build five mRNA-based vaccines and monoclonal antibodies.

Does GSK have an influenza vaccine?

GlaxoSmithKline has been awarded different government contracts for influenza vaccine doses. In February 2022, The US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority extended its agreement with GSK to provide influenza vaccine for the US government.

Aside from the US government, GSK has contracts and agreements for the production of influenza supply doses in Europe, Canada, and the World Health Organization. The company has also developed different vaccine delivery methods for influenza, such as Afluria Quadrivalent, Fluarix Quadrivalent, FluLaval Quadrivalent, Fluzone Quadrivalent, and more.

Getting ahead of diseases with science, technology, and talent

GlaxoSmithKline government contracts have positively impacted the world’s fight against diseases. With its large scale and long history of expertise, GSK is on a mission to improve the health of 2.5 billion people worldwide in the next ten years.

What Are The Top Pfizer Government Contracts?
Published on
What Are The Top Pfizer Government Contracts?

Pfizer is one of the leading health care providers in the country. Since the COVID-19 pandemic, the company has filled the demand to supply vaccines in the U.S. and internationally. Read here to know the top Pfizer government contracts.

Pfizer vaccine distribution

Pfizer Government Contracts

Pfizer has led the distribution of vaccines since the pandemic started. It also received and signed multiple agreements to control viral diseases in the country.

1. U.S. Government Paxlovid COVID-19 Pill

  • Federal Agency: U.S. Government
  • Value: $5.3 Billion

The US government spends $530 on each 5-day course of the COVID-19 pill Paxlovid made by Pfizer. However, the contract for the first 10 million medicines would allow the government to negotiate a lower price if other countries secure a better pharma deal. Overall, the government allotted $5.3 billion for this agreement.

Under this contract, the US government may revoke emergency use authorization for Paxlovid, and Pfizer has agreed to purchase any new treatment courses from the US government.

2. U.S. Government COVID Vaccine Deal

  • Federal Agency: U.S. Government
  • Value: $3.2 Billion
  • Designation: For the general public

Pfizer Inc and BioNTech SE received a government contract worth $3.2 Billion last June 2022. The agreement aims to produce 105 million doses of the COVID-19 vaccine that should be available to the public in the upcoming summer of 2022.

Under this deal, the two companies must supply the retooled Omicron-adapted vaccine and complete the pending regulatory clearance. The companies will also focus on developing vaccines as the Omicron cases increase during winter.

The new contract might also help Pfizer and BioNTech sell and distribute more shots in 2022. This year, Pfizer considers that the COVID-19 vaccine will bring in $32 billion in sales.

3. U.S. Army to buy 500 million COVID-19 Vaccines

  • Federal Agency: U.S. Army
  • Contract Type: Firm-fixed-price contract
  • Value: $3.5 Million
  • Contract Period: Until Dec. 31, 2022
  • Designation: For International Donations

A firm-fixed-price contract was given to Pfizer Inc. to purchase 500 million COVID-19 vaccines for international donations. The work will be done in New York, New York, and is expected to conclude by December 31, 2022. At the time of the award, the Army had spent the contract amount of $3,500,000,001 on research, development, testing, and evaluation for FY 2021. The contracting activity is the U.S. Army Contracting Command at Aberdeen Proving Ground in Maryland.

4. US-Pfizer COVID-19 Contract

  • Federal Agency: U.S. Army
  • Value: $10 Billion
  • Contract Period: 2 years
  • Designation: Commercial and public use 

The United States government has agreed to spend $10 billion to purchase 500 million doses of Pfizer’s COVID-19 vaccine, with a clause in the contract indicating the current price of $20 per dosage.

In December 2020, the US Army spent $10,016,418,500 to contract Pfizer to provide 500 million doses of vaccine, which cost $20 each. The company must be able to give the last set of vaccines on April 30, 2022. This contract only provides the first two vaccine shots and does not cover the booster shots.

About Pfizer

Pfizer biopharmaceutical company

Pfizer is one of the leading biopharmaceutical companies in the world. The organization promotes medical innovation and provides access to medicines that might otherwise be out of reach for people in underprivileged areas.

Some of the significant services of the company include the following:

  • Grants – The company supports independent activities and enhances patient care by assisting underprivileged communities worldwide.
  • Political Partnership – Pfizer helps the public to understand healthcare, public policy engagement, and illness prevention.
  • Healthcare Collaboration – Through its funding of research networks, Pfizer encourages partnerships to discover healthcare innovations.
  • Prescription Pricing – Even if healthcare providers and insurance companies decide how much patients will pay for their prescriptions, Pfizer’s pricing strategy for their medicine is to make it convenient and help people live healthier and more productive.

Pfizer Business Segments

Pfizer’s operations are divided between the Biopharmaceuticals Group and the Pfizer CentreOne segments.

Pfizer Biopharmaceuticals Group

Pfizer is the fourth-largest pharmaceutical company in the world by revenue based on the Fortune listing in 2021. By making the COVID-19 vaccine alone, the company made up almost half its annual revenue, or $36.8 billion.

The Biopharmaceuticals Group reports revenue in the following medicinal field:

  • Internal Medicine
  • Oncology
  • Hospital
  • Vaccines
  • Inflammation and Immunology
  • Rare Disease

Pfizer CentreOne®

Pfizer CentreOne® is a world-class global contract development and manufacturing organization (CDMO), supplying customized APIs and intermediates worldwide for over four decades.

Pfizer experts support Pfizer CentreOne® in manufacturing medicines by providing its facilities. Pfizer invests approximately $1B yearly in manufacturing to improve infrastructure and procedures.

Pfizer FAQs

What does Pfizer do?
Pfizer works with local and international healthcare and pharmaceutical industries and supplies them with the best medicines, vaccines, and other wellness products. Pfizer consists of a team of professionals and experts who work to provide treatments and prevent some of the world’s deadliest diseases in both developed and developing countries.

What Is Pfizer-BioNTech COVID-19 Vaccine?
BioNTech, a German biotechnology company, partnered with the American pharmaceutical giant Pfizer to manufacture, distribute, and conduct clinical trials for the Pfizer-BioNTech COVID-19 Vaccine or BNT162b2. The vaccine is effective in preventing COVID-19 caused by the SARS-CoV-2 virus.

What Is Operation Warp Speed?
Operation Warp Speed was a government program that helped many COVID-19 vaccine candidates move faster. The current government under the Biden administration is working hard to make an innovative Covid COVID vaccine. Major companies like Pfizer and Moderna have shown that it only takes a few months to make booster shots suited to each variant.

Does Pfizer have an Omicron booster?
Pfizer and BioNTech have released new clinical data for the Omicron BA.4/BA.5-Adapted Bivalent Booster. This research shows that the new booster can give adults a much more robust immune response than the original COVID-19 vaccine.

Pfizer Premier Biopharmaceutical Company

Premier Biopharmaceutical Company

Over the years, Pfizer has ranked sixth among top government contractors. The company has developed numerous disease control treatments that helped governments move forward from the pandemic. Pfizer continues developing medicines and vaccines with the leaders and experts to combat even future diseases.

What are the Top Leidos Government Contracts?
Published on
What are the Top Leidos Government Contracts?

Currently headquartered in Reston, Virginia, Leidos — an American company providing aviation, defense, information technology (Lockheed Martin IS&GS), and biomedical research — works extensively with the United States Department of Defense, the United States Department of Homeland Security, and the United States Intelligence Community. Check out the Leidos government contracts the company has won and handled successfully over the past years.

Leidos, Fortune 500 science and technology leader

1. U.S. Army Contract for Existing Night Eagle System Support

  • Federal Agency: U.S. Army
  • Contract Date: January 2020
  • Contract Value: $72,575,612
  • Task: Provide intelligence, surveillance, and reconnaissance system support services

Leidos has been awarded a 27-month contract of $72,575,612 to continue providing the U.S. Army with intelligence, surveillance, and reconnaissance system support services.

The Army promptly committed the total estimated value of the award to operations and maintenance expenditures allocated for fiscal years 2020 to 2022. The duration of work in Reston, Virginia, ended last April 25, 2022.

The Department of Defense also announced that the company would support the existing Night Eagle platform under the firm-fixed-price contract.

2. Indefinite-Delivery/Indefinite-Quantity Contract from the Department of Navy

  • Federal Agency: Department of Navy
  • Contract Date: February 2020
  • Contract Value: $7,729,639,286
  • Task: Revamp several data networks

The Department of Navy (DoN) gave Leidos a contract worth $7,729,639,286 to revamp several data networks, as per the Pentagon. This is according to DoN’s initiative to modernize the Navy’s outdated information technology infrastructure.

The award to Leidos of the Service Management, Integration and Transport (SMIT) contract enabled the digital transformation of enterprise networks, which is the backbone of the Department of Navy’s operations. For nine months, the contract initiated the modernization of the Navy-Marine Corps Intranet (NMCI), which is utilized by nearly every sailor and marine in the DoN.

Helping out the federal government with such forward looking statements and results

3. U.S. Army Firm-Fixed-Price Contract for Automated Installation Entry System Support

  • Federal Agency: U.S. Army
  • Contract Date: July 2020
  • Contract Value: $58,487,824
  • Task: Provide maintenance for the Automated Installation Entry platform

The U.S. Army granted Leidos a two-year firm-fixed-price contract worth $58,487,824 to assist with the need for an electronic system designed to safeguard personnel and visitor access to military locations.

As per the Department of Defense, the company would provide maintenance for the branch’s Automated Installation Entry platform until July 27, 2022.

4. Contract to Support the Naval Array Technical Support Center Facility Operation

  • Federal Agency: U.S. Navy
  • Contract Date: October 2020
  • Contract Value: $149,238,311
  • Task: Provide services and supplies for the NATSC facility operation

Leidos clinched an indefinite-delivery/indefinite-quantity contract with cost-plus-fixed-fee, cost reimbursement, and firm-fixed-price provisions worth $149,238,311.

About 99% of the work was done in Newport, Rhode Island, and the rest is distributed in Reston and Virginia Beach.

This contract, projected to be completed in November 2025, offered services and supplies for the operation of the Naval Array Technical Support Center site.

Leidos defense group president

5. U.K. Navy’s Cost-Plus-Fixed-Fee, IDIQ Contract Action for Engineering Support Services

  • Federal Agency: U.K. Navy
  • Contract Date: May 2021
  • Contract Value: $38,047,689
  • Task: Provide engineering support services

Leidos was awarded a cost-plus-fixed-fee, indefinite-delivery/indefinite-quantity contract action with a total estimated value of $38,047,689 that is expected to be done by May 2026.

This contract includes purchases from the United Kingdom government under the Foreign Military Sales (FMS) program. Leidos was tasked to provide engineering support services for planning, designing, developing, specifying, fabricating, installing, integrating, and supporting the British Undersea Test and Evaluation Center High Gain Measurement System.

6. Cost-No-Fee, Firm-Fixed-Price Contract for Technology Refresh and Upgrade from the U.S. Army

  • Federal Agency: U.S. Army
  • Contract Date: January 2022
  • Contract Value: $104,512,000
  • Task: Perform technology refresh, concurrency upgrades, and production

A $104,512,000 cost-no-fee, firm-fixed-price contract was awarded to Leidos by the U.S. Army’s Program Executive Office for Simulation, Training, and Instrumentation.

The goal is to modernize the service’s gunnery training simulation systems within a period of five years with an estimated completion date of January 24, 2027. The work will be done in Orlando, Florida.

Leidos will provide technology refreshes and concurrency updates on simulators. Gunnery Training Simulators integrate the body of a weapon into a virtual reality system using a computer-based simulator. These are used to supplement training on a variety of weapons operated by crews.

national level leaders working on vital missions

7. DISA Defense Enclave Services (DES) Contract for Defense Information Systems Agency

  • Federal Agency: Defense Information Systems Agency
  • Contract Date: February 2022
  • Contract Value: $11,504,145,491
  • Task: Provide integrated, standardized, and cost-effective IT command and control solutions

The Defense Information Systems Agency awarded Leidos a competitive, single-award, indefinite-delivery/indefinite-quantity contract worth $11,504,145,491, with firm-fixed-price, labor hour, and cost-reimbursable line items. The aim of the agreement was to combine the networks of non-combat defense support organizations.

With the company’s technological expertise, Leidos would oversee what DISA refers to as the Fourth Estate Network Optimization (4ENO) initiative, which aims to modernize and migrate the 22 Fourth Estate agencies and field activities of the Department of Defense to a single platform. This platform is called DoDNet.

8. Contract to Increase the Speed and Agility of Defense Intelligence Agency Operations

  • Federal Agency: Defense Intelligence Agency
  • Contact Date: June 2022
  • Contract Value: $84,938,062
  • Task: Provide automation and other services for the operations

The Defense Intelligence Agency awarded Leidos a 10-year, indefinite-delivery/indefinite-quantity contract worth $84,938,062 to offer automation and other services in support of its operations.

The contract will be performed in the National Capital Region until June 14, 2032.

Leidos would help the DIA design and implement a data-centric architecture with cloud computing capability for digital enrichment tool development, automate labor-intensive and time-consuming agency processes, and provide data access to external customers and partners.

9. Task Order Under an IDIQ Contract to Support DOD’s Chief Information Officer

  • Federal Agency: Department of Defense
  • Contract Date: July 2022
  • Contract Value: $72,000,000
  • Task: Provide non-personal services to the Office of the Department of Defense Chief Information Officer

Under an indefinite-delivery/indefinite-quantity contract awarded on August 3, 2018, a $72,000,000 task order was also awarded to Leidos to provide non-personal services to the Office of the Department of Defense Chief Information Officer with regular operations and maintenance, procurement, research, testing development and evaluation.

The contract with a cumulative total of $360,000,000, is set to be completed by August 2, 2023.

Frequently Asked Questions

Leidos support mission success up to the end

Below are some of the frequently asked questions about Leidos Holdings, Inc.:

Is Leidos a government contractor?

Leidos has collaborated with government agencies for years to address technological obstacles and develop innovative efficiency.

To promote citizens’ safety and well-being, the company supports vital programs that expedite identity theft recovery, streamline paper tax filings, preserve electronic health records, improve consumer fraud investigations, assist census data collection, and facilitate scientific research.

How long does it take to win a government contract?

Typically, it takes around 18 to 24 months for a government contractor to secure their first contract. That’s why patience is important in this field.

What contracts does Leidos have?

Firm Fixed Price (FFP) Contracts, Cost Plus Fixed Fee Contracts, Indefinite-Delivery/ Indefinite-Quantity are the types of contracts that Leidos Holdings, Inc. have.

What companies does Leidos own?

Leidos’ wholly-owned and majority-owned subsidiaries:

  • 1901 Group
  • Dynetics
  • Gibbs & Cox
  • Leidos Biomedical Research
  • Leidos Digital Solutions
  • BEONTRA
  • QTC
  • Leidos Engineering
  • Systems Made Simple
  • Varec

Leidos Facing the World’s Toughest Challenges

Leidos' government and commercial customers

Over the past 50 years, Leidos has worked in some of the most sophisticated areas of science and technology to provide vital solutions to its customers’ toughest challenges. This is what makes the company stand out and be the best at what it does.

1 … 674 675 676 677 678 … 2,617